Prisca Chinonso Njoku
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Prisca Chinonso Njoku has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abolaji Samson Olagunju
Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, 05508-000 São Paulo, Brazil
1 shared publication - Aderinsola Racheal Adebisi
Department of Biochemistry, University of Lagos, Yaba, Lagos State, Nigeria
1 shared publication Akinwale John Faniyi
1 shared publication- Alfred Akinlalu
Biomedical Focus, Department of Electrical and Computer Engineering, University of Denver, 2155 E Wesley Ave., Denver, CO, 80208, USA; Knoebel Institute of Healthy Aging, University of Denver, 2155 E Wesley Ave., Denver, CO, 80208, USA
1 shared publication - Amos Olalekan Abolaji
Molecular Drug Metabolism and Toxicology Unit, Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria
1 shared publication Ayokanmi Joseph Aremu
Department of Microbiology, Kwara State University, Malete, Kwara State, Nigeria
1 shared publication
Latest Publications
- Open Access
- 22 June 2023
- Published by Springer Nature in Research Square
The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.
- 22 June 2023
- Published by Springer Nature in Research Square
Open AccessThe inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.
- Open Access
- 28 August 2022
- Published by Elsevier in Scientific African
- Vol. 17
Recent developments in the significant effect of mRNA modification (M6A) in glioblastoma and esophageal cancer
- 28 August 2022
- Published by Elsevier in Scientific African
- Vol. 17
Open AccessRecent developments in the significant effect of mRNA modification (M6A) in glioblastoma and esophageal cancer